| Call Number (LC) | Title | Results |
|---|---|---|
| QV38 I6055n 1976 | Nutrition and drug interrelations | 1 |
| QV38 M587 1982 | Metabolic basis of detoxication metabolism of functional groups / | 1 |
| QV38 N2785r 1983 | Receptor-mediated targeting of drugs | 1 |
| QV39 | Antibiotics : Targets, Mechanisms and Resistance. | 1 |
| QV95 R158a 1984 | Aspirin and the salicylates | 1 |
| QV129 K14a 1973 | The amphetamines; toxicity and addiction. | 1 |
| QV241 | Biological Drug Products : Development and Strategies. | 1 |
| QV241 .R635 2020 | Gestión Clínica, Incentivos y Biosimilares | 1 |
| QV268.5 S998i 1982 | Interferons | 1 |
| QV269 A668d 1981 | Doxorubicin anticancer antibiotics / | 1 |
| QV276 U84m 1981 | The Mechanism of gated calcium transport across biological membranes | 1 |
| QV350 F834b 1989 | Biochemistry of antimicrobial action / | 1 |
| QV354 S541e 1982 | The enchanted ring : the untold story of penicillin / | 1 |
| QV736 |
Pharmaceutical Project Management. Mass Spectrometry Handbook. |
2 |
| QV744 |
NMR of Biomolecules. Applications of transition metal catalysis in drug discovery and development an industrial perspective / Applications of transition metal catalysis in drug discovery and development : an industrial perspective / |
3 |
| QV744 M192m 1984 | Multidimensional pharmacochemistry design of safer drugs / | 1 |
| QV745 | Scaffold hopping in medicinal chemistry / | 2 |
| QV748 .D629 2005 | DNA pharmaceuticals : formulation and delivery in gene therapy, DNA vaccination, and immunotherapy / | 1 |
| QV771 |
Drugs and Laboratory Parameters. Clinical Trials : Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines. |
2 |
| QV771 A168h 1973 | How safe is safe? The design of policy on drugs and food additives. | 1 |
